- Home
- XIN vs CMMB Comparison
XIN vs CMMB Comparison
Compare XIN & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XIN
- CMMB
- Stock Information
- Founded
- XIN 1997
- CMMB 2004
- Country
- XIN China
- CMMB Israel
- Employees
- XIN N/A
- CMMB N/A
- Industry
- XIN Homebuilding
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- XIN Consumer Discretionary
- CMMB Health Care
- Exchange
- XIN Nasdaq
- CMMB Nasdaq
- Market Cap
- XIN 15.7M
- CMMB 15.8M
- IPO Year
- XIN N/A
- CMMB N/A
- Fundamental
- Price
- XIN $4.33
- CMMB $1.51
- Analyst Decision
- XIN
- CMMB Strong Buy
- Analyst Count
- XIN 0
- CMMB 3
- Target Price
- XIN N/A
- CMMB $5.67
- AVG Volume (30 Days)
- XIN 319.1K
- CMMB 231.4K
- Earning Date
- XIN 01-01-0001
- CMMB 11-07-2024
- Dividend Yield
- XIN N/A
- CMMB N/A
- EPS Growth
- XIN N/A
- CMMB N/A
- EPS
- XIN N/A
- CMMB N/A
- Revenue
- XIN $667,143,185.00
- CMMB N/A
- Revenue This Year
- XIN N/A
- CMMB N/A
- Revenue Next Year
- XIN N/A
- CMMB N/A
- P/E Ratio
- XIN $0.64
- CMMB N/A
- Revenue Growth
- XIN N/A
- CMMB N/A
- 52 Week Low
- XIN $1.92
- CMMB $0.42
- 52 Week High
- XIN $7.05
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- XIN 56.60
- CMMB 43.28
- Support Level
- XIN $2.49
- CMMB $1.29
- Resistance Level
- XIN $7.05
- CMMB $1.58
- Average True Range (ATR)
- XIN 0.64
- CMMB 0.15
- MACD
- XIN 0.23
- CMMB -0.04
- Stochastic Oscillator
- XIN 40.50
- CMMB 39.29
About XIN Xinyuan Real Estate Co Ltd
Xinyuan Real Estate Co Ltd operates as a real estate developer and property manager in China. It focuses on developing residential projects, which typically consist of multiple residential buildings that include multi-layer apartment buildings, and others. Its several projects include auxiliary services and amenities such as retail outlets, leisure and health facilities, kindergartens, and schools. It aims to provide comfortable and convenient real estate-related products and services to middle-class consumers.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.